David Moadel

David Moadel

InvestorPlace Contributor

Expertise: Stocks, Options, Precious metals, Bitcoin, Altcoins

Education: Master's degree in education from the American College of Education, Bachelor's degree in education from Florida Atlantic University, Associate's degree in liberal arts from Palm Beach Community College

About David:
David Moadel is a financial writer for InvestorPlace.com. He has a master’s degree in education and has authored financial content for multiple websites.

David is also active as a social media influencer, with tens of thousands of followers on YouTube, Twitter, StockTwits, and other popular sites. David writes on topics ranging from stocks to cryptocurrencies, options, precious metals, bonds, futures, and other areas of finance.

Focusing on data rather than emotions, David is always on the lookout for new pathways to financial freedom. Count on David for wealth-building strategies and resources for investors and traders of all financial backgrounds.

You can follow David on YouTube, Twitter, StockTwits and LinkedIn.

Recent Articles

Better Customer Service Should Bolster the Case for Robinhood

By David Moadel, InvestorPlace Contributor

HOOD stock has disappointed some investors, and an ominous threat from the SEC certainly isn't helping. Still, there's good news to report.

Dutch Bros Stock Is Served Up Hot and Fresh, but Not Cheap

By David Moadel, InvestorPlace Contributor

Post-IPO, BROS stock traders are talking about an emerging "Starbucks killer" - but let's first consider if Dutch Bros can compete.

AT&T Stock Should Be in Everyone’s Portfolios

By David Moadel, InvestorPlace Contributor

T stock has fallen despite a robust and visionary outlook from AT&T's CEO, so don't expect the shares to be "dead money" for much longer.

Why Cathie Wood’s Skillz Share Sale Shouldn’t Deter Investors

By David Moadel, InvestorPlace Contributor

It's time to sift through the wreckage of SKLZ stock and discover an underappreciated gem as Skillz introduces new gaming experiences.

Novavax Stock Got Merck-ed, but Don’t Dump Your Shares Now

By David Moadel, InvestorPlace Contributor

NVAX stock still has plenty of value as Novavax has a rich and diverse clinical pipeline, including a promising influenza vaccine candidate.

Load More